MedTrace Logo

Safety of Three Formulations of Ketasyn Administered for 14 Days in Healthy Elderly

NCT00660088 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2008-10-08

No results posted yet for this study

Summary

AC-1202 (Ketasyn) is a nutritional beverage currently being studied in neurodegenerative conditions including Alzheimer's disease. The current study is a randomized, open-label trial to compare the safety, tolerability, and PK profiles of 3 formulations of Ketasyn administered on a daily basis for 14 days, with and without a 7-day titration period, in normal, healthy elderly volunteers.

Conditions

Interventions

OTHER

Ketasyn

10g for 7 days, 20g for 7 or 14 days

Sponsors & Collaborators

  • Cerecin

    lead INDUSTRY

Principal Investigators

  • Lauren Costantini, PhD · Cerecin

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2008-06-30
Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00660088 on ClinicalTrials.gov